Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases
June 25 2024 - 7:05AM
Business Wire
Anumana, a leading AI-driven health technology company and
portfolio company of nference, and InfoBionic.Ai, a digital health
company specializing in remote cardiac monitoring and diagnostic
solutions, today announced a joint research collaboration agreement
to develop and commercialize the next generation of remote cardiac
care solutions, combining Anumana’s breakthrough ECG-AI™ technology
and InfoBionic.Ai’s MoMe ARC® platform.
By leveraging Anumana's ECG-AI algorithms, developed and
validated in collaboration with Mayo Clinic, this initiative aims
to enhance InfoBionic.Ai’s MoMe ARC Platform’s ability to detect
and intervene in cardiac diseases earlier in the remote patient
monitoring setting, with the potential to improve patient outcomes.
Anumana and InfoBionic.Ai, both Mayo Clinic portfolio companies,1,2
will continue to work closely with Mayo Clinic under this research
agreement.
“It is exciting to see the convergence of our pioneering work in
artificial intelligence and remote patient monitoring through this
new partnership between Anumana and InfoBionic.Ai,” said Peter
Noseworthy, MD, chair of the Heart Rhythm Services Division of
Cardiovascular Medicine at Mayo and a board director at
InfoBionic.Ai. “By combining InfoBionic.Ai’s remote monitoring
solutions with Anumana’s innovative ECG-AI algorithms, including
the FDA-cleared algorithm for detecting low ejection fraction
(LEF), we aim to equip healthcare providers with the latest
cutting-edge tools to detect underlying cardiac conditions earlier,
enabling timely intervention and personalized care. It’s a
thrilling time for cardiology."
“This collaboration marks an important step in Anumana’s mission
to revolutionize cardiac care by enhancing the power of ECG with
AI,” said Maulik Nanavaty, CEO of Anumana. “Since the founding of
Anumana, our vision has been to elevate the utility of ECG with AI
across all the settings in which ECGs are used. By joining forces
with InfoBionic.Ai, we are expanding our capabilities from 12 leads
in clinical settings to wearable lower-lead ECGs in patients’
homes. We look forward to bringing our AI technology to meet
patients and physicians where they are, ultimately benefiting both
worldwide.”
Under the agreement, InfoBionic.Ai and Anumana will develop and
integrate Anumana's ECG-AI algorithms, starting with the FDA
cleared ECG-AI LEF algorithm, into InfoBionic.Ai's continuous and
remote cardiac monitoring platform, allowing the ability to detect
LEF and other conditions through the remote monitoring of cardiac
activity. The companies will also work together to validate the
clinical utility of the integrated solution and seek regulatory
clearance to bring this technology to market.
Anumana has received FDA Breakthrough Device Designation for
four of its algorithms: low ejection fraction, pulmonary
hypertension, cardiac amyloidosis, and hyperkalemia. Its ECG-AI
platform won the 2024 MedTech Breakthrough Award for “Best New
Technology Solution- Cardiology.” ECG-AI LEF, the company’s
FDA-cleared AI algorithm using routine 12-lead ECG data to detect
low ejection fraction (LEF), a commonly undiagnosed indicator of
heart failure,3 received U.S. FDA clearance in September 2023 and
is currently under review in Europe. Anumana has demonstrated that
its ECG-AI technology can be adapted to lower-lead ECG devices
while maintaining a high degree of performance. A version of the
neural network used in Anumana’s FDA cleared ECG-AI LEF algorithm
has shown the algorithm to be effective in detecting low ejection
fraction using single-lead wearable ECG devices.4
InfoBionic.Ai’s MoMe ARC is the first and only continuous 6-lead
FDA-cleared platform leveraging leading-edge AI analysis and native
business intelligence. MoMeARC is a solution that includes a 4-in-1
Gateway device that seamlessly transitions between 2-day in
addition to extended Holter tests, Event and MCT modes remotely,
streamlining patient monitoring time and minimizing delays.
About InfoBionic.Ai
InfoBionic.Ai’s digital technology has transformed the
efficiency and economics of cardiac remote patient monitoring. The
company’s vision for its FDA-cleared third-generation platform, the
MoMe ARC®, is to remove the roadblocks hindering virtual and remote
diagnosis and decision-making. The Massachusetts-based team of
seasoned entrepreneurs has had successful careers in healthcare,
IT, medical devices, and mobile technology, and brings specific
expertise in remote monitoring and cardiology.
Visit https://infobionic.ai.
About Anumana
Anumana is a leading AI-driven health technology company
leveraging cutting-edge AI and industry-leading translational
science to unlock the electrical language of the heart as never
before. The company was founded by nference in collaboration with
Mayo Clinic to leverage the clinical and technical expertise of
both organizations to develop innovative ECG-AI technology into a
clinically meaningful, medical-grade, and easy to use tool for
clinicians to advance patient care. Anumana’s software-as-a-medical
device (SaMD) ECG-AI™ solutions aim to detect diseases earlier
using standard-of-care ECG readings, enabling clinicians to enhance
and improve care with real-time AI insights.
Anumana’s lead algorithm, ECG-AI™ LEF is now available in the
U.S. To learn more about how the algorithm can help clinicians
identify low ejection fraction (LEF) earlier and schedule a demo,
visit us at ECG-AI LEF.
References
-
https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-launches-new-technology-platform-ventures-to-revolutionize-diagnostic-medicine/
-
https://infobionic.ai/press/infobionic-enters-know-how-agreement-mayo-clinic/
- Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard
J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic
Dysfunction. European Cardiology Review 2020, 15:e13;
https://doi.org/10.15420/ecr.2019.14.
- Attia, Z.I., Harmon, D.M., Dugan, J. et al. Prospective
evaluation of smartwatch-enabled detection of left ventricular
dysfunction. Nat Med 28, 2497–2503 (2022).
https://doi.org/10.1038/s41591-022-02053-1
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625164507/en/
Anumana Media Contact: Sam Choinski Pazanga
schoinski@pazangahealth.com (860) 301-5058
InfoBionic.Ai Media Contact Karlo Jo Helms JOTO PR™
727-777-4619 jotopr.com